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Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Hyper-
cholesterolemia is a known complication of the nephrotic syndrome.
Patients with persistent proteinuria and prolonged hypercholesterol-
emia are probably at increased risk for cardiovascular disease. Until
recently there has been no safe and effective treatment for this disorder.
The effects of gemfibrozil on plasma lipids and lipoproteins in hyper-
cholesterolemic patients with the nephrotic syndrome were therefore
studied. Eleven patients with the nephrotic syndrome were studied in a
randomized, double-blind placebo-controlled trial with six-week treat-
ment periods. Gemfibrozil 600 mg or placebo was administered twice a
day. There was a third unblinded period in which seven patients
received gemfibrozil plus the bile acid-binding resin, colestipol, 10
grams twice a day. Gemfibrozil treatment produced a marked reduction
in plasma triglyceride (51%, P = 0.001) and a 15% decrease in plasma
total cholesterol (P = 0.003). Low density lipoprotein cholesterol
decreased 13% (P > 0.05), high density lipoprotein cholesterol in-
creased 18% (P = 0.006) and the ratio of low density lipoprotein to high
density lipoprotein cholesterol fell 26% (P = 0.01). Apolipoprotein A-I
was unchanged while apolipoprotein B decreased 26% (P = 0.006).
Four patients were unable to complete period 3 because of gastrointes-
tinal symptoms. The remaining patients had further improvement in
plasma lipids and lipoproteins with the combined therapy: total choles-
terol further decreased 26%, triglycerides decreased 17%, low-density
lipoprotein cholesterol decreased 36%, high-density lipoprotein choles-
terol did not change and the ratio of low-density lipoprotein to high-
density lipoprotein cholesterol fell 33%. Gemfibrozil improved lipid and
lipoprotein cardiovascular risk factors without major toxicity. Persist-
ent elevations in total plasma and low-density lipoprotein cholesterol
during gemfibrozil treatment, however, indicate the need for individu-
alized drug therapy.
Long-standing hypercholesterolemia from diverse causes is a
potent risk factor for premature atherosclerosis. Recent large-
scale clinical trials have shown convincingly that lipid-lowering
drugs, including gemfibrozil, are effective in reducing cardio-
vascular morbidity in adult males [1—4].
Hyperlipidemia has been recognized as a consistent feature
of the nephrotic syndrome for more than a half century [5].
Clinical observations strongly suggest [6—9] that hypercholes-
terolemic nephrotic patients (who as a group exhibit multiple
cardiovascular risk factors [9]) are at risk for premature isch-
emic vascular disease, just as are patients with primary hyper-
cholesterolemia.
Nonetheless, authorities have disagreed [10—12] over whether
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or not hyperlipidemia in nephrotic syndrome ought to be treated
with lipid-lowering agents. Most believe that such treatment is
not appropriate in patients with minimal change disease whose
proteinuria and lipoprotein abnormalities are glucocorticoid-
responsive and transient. Reluctance to use lipid-lowering
drugs in patients with other forms of nephrotic syndrome has
been due to inadequate information about their effects on serum
lipids and lipoproteins, and to uncertainty about the long-term
safety and efficacy of lipid-lowering drugs in reducing risk of
cardiovascular disease in general.
Clofibrate, a fibric acid congener, produces myositis in pa-
tients with the nephrotic syndrome [13] and in rats with
experimental nephrosis [14], so clinicians have either avoided
clofibrate altogether or used it at reduced dosage [15, 16].
Gemfibrozil, another fibric acid congener which is less exten-
sively bound to plasma proteins, was used by Manninen,
Malkonen and Eisalo to treat six nephrotic subjects without
reported toxicity [17]. Serum total cholesterol, triglyceride,
beta- (low density lipoprotein, LDL) and pre-beta (very-low
density lipoprotein, VLDL) lipoprotein concentrations were
reduced, whereas alpha lipoprotein (high density lipoprotein,
HDL) concentrations were increased [17]. On the basis of these
promising reports, we conducted a randomized, double-blinded
placebo-controlled study of gemfibrozil treatment in 11 ne-
phrotic volunteers in whom more extensive lipid and lipopro-
tein analyses were performed. Plasma lipid and lipoprotein
concentrations were altered in ways expected to lead to re-
duced risk of ischemic vascular disease. Given these findings
and the results of the Helsinki study of the effects of gemfibrozil
on coronary morbidity in the non-nephrotic population [4],
gemfibrozil can be considered as a rational choice for the
treatment of hyperlipidemic patients with established nephrotic
syndrome. However, a substantial number of nephrotic patients
so treated will have persistent abnormalities that require ad-
junctive or alternative drug therapy.
Methods
Patient selection
Nephrotic syndrome was defined as proteinuria of more than
3.0 gIdl, serum albumin of less than 3.5 g/dl, peripheral edema,
and hyperlipidemia with total serum cholesterol exceeding the
age- and sex-specific 95th percentile [18]. Eleven patients with
the nephrotic syndrome and serum creatinine less than 3.0
mg/dl were entered into a controlled, randomized, double-blind
trial. Informed consent conforming to the guidelines of the
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Table 1. Patient characteristics at entry into study
No. Age Sex Renal disease
Serum
creatinine
Plasma
cholesterol
Plasma
triglycerides
Plasma HDL
cholesterol
Plasma LDL
cholesterol
mg/dl
1
2
3
4
5
6
7
8
9
10
11
26
22
46
73
25
26
40
31
58
62
32
F
M
M
M
M
F
M
M
F
M
F
Lupus nephritis
Membranous nephropathy
Mesangial proliferative GN
Membranous nephropathy
Mesangial proliferative GN
Lupus nephritis
Membranoproliferative GN
Mesangial proliferative GN
Diabetic nephropathy
Diabetic nephropathy
Lupus nephritis
1.1
1.3
1.4
2.5
2.0
1.9
1.5
1.2
1.2
1.2
1.6
575
301
299
538
312
487
284
510
387
433
384
240
677
322
281
656
308
212
198
241
237
289
59
32
31
53
38
47
41
37
32
58
44
468
134
204
429
143
378
201
433
307
328
282
Abbreviation GN is glomerulonephritis.
Institutional Review Board of the University of Utah was
obtained.
Patient characteristics are shown in Table 1. Except for two
patients with well-established diabetic nephropathy (long-
standing insulin-dependent diabetes mellitus, diabetic retinop-
athy and proteinuria), all underwent renal biopsy. None had
familial hypercholesterolemia by history. Exclusion criteria
included alcoholism, thyroid disease, previous myocardial in-
farction, malignancy or surgical procedures to lower lipids. All
patients were on their usual diet. The diet was monitored to
ensure that it did not change for the duration of the study.
Study design
Patients were withdrawn from lipid-lowering drugs for at
least six weeks before the start of study. Those who required
other drugs known to affect lipid metabolism, including antihy-
pertensives and glucocorticoids, were kept on constant doses
throughout the study. All were on stable diets, and all had two
screening blood tests and complete history and physical exam-
inations before entry. Patients meeting the selection criteria
were then entered into a double blind, randomized, placebo-
controlled crossover study of gemfibrozil; this was followed by
an open label study of gemfibrozil and colestipol together. Each
of the three sequential treatment periods was for six weeks
without intervening washout periods. During the first two
periods gemfibrozil (600 mg) or placebo was administered as
two capsules twice a day taken immediately before the morning
and evening meals (total dose 1,200 mg/day). During the third
unblinded period patients received gemfibrozil 600 mg twice a
day along with cole stipol 10 grams twice a day. Seven of the 11
patients agreed to enter the third phase of the study; only three
of the seven completed this phase.
Subjects were seen every two weeks. Weight, blood pres-
sure, complete blood count, urinalysis, 24-hour urine for pro-
tein and creatinine, and a serum biochemical profile including
creatinine, urea nitrogen, sodium, potassium, chloride, bicar-
bonate, calcium, phosphorus, SGOT, SGPT, bilirubin, alkaline
phosphatase, total protein, albumin, uric acid and creatine
phosphokinase were obtained. These biochemical assays were
carried out in the Clinical Laboratories at the University of
Utah Hospital. Information about adverse reactions was solic-
ited and pill counts were performed to verify compliance.
Lipid and apolipoprotein analysis
Blood for plasma total cholesterol, triglycerides, high density
lipoprotein, and apolipoprotein analysis was taken from seated
patients after a 12 to 15 hour fast and collected in sodium
potassium ethylenediamine tetraacetate, 2.63 m final concen-
tration [19]. At the beginning of each period total serum
concentrations of apolipoproteins A-I and B (apoA-I and apoB,
respectively) were measured by a rate immunonephelometric
assay [20]. In addition, electrophoresis of ultracentrifugally-
separated lipoproteins with density < 1.006 g/ml was carried
out to exclude the presence of beta-migrating VLDL. Plasma
LDL concentration was calculated for all samples (including
those from the 2 subjects with triglyceride concentrations more
than 400 mg/dl) using the Friedewald equation [21]. Although
LDL cholesterol is underestimated in hypertriglyceridemic
samples, this would bias against the a priori hypothesis that
LDL cholesterol is reduced by gemfibrozil therapy.
Statistical analyses
Biochemical variables are expressed as means (4 values for
the placebo, and 3 each for the gemfibrozil and gemfibrozil plus
colestipol periods) standard errors. Since some measure-
ments were skewed or platykurtotic, statistical differences
between paired observations were examined both by Student's
paired t-test and with Wilcoxon's rank order test for non-
parametric data. In all cases estimates of statistical significance
were consistent between the two tests. Therefore, only results
obtained by the Wilcoxon's test are presented. Statistical
significance was declared at P < 0.05.
Results
All 11 patients completed the first two study periods. Serum
creatinine, blood urea nitrogen, serum albumin and 24-hour
urinary protein excretion did not differ between the placebo and
gemfibrozil periods (Table 2). Systolic blood pressure did not
change significantly with gemfibrozil (136 4 vs. 129 4 mm
Hg in the placebo and gemfibrozil periods, respectively)
whereas diastolic blood pressure was significantly lower (85
2 vs. 82 2 mm Hg, P < 0.05).
During gemfibrozil treatment plasma triglycerides fell 50.7%
(P = 0.001); total plasma cholesterol fell 15.1% (P = 0.003, Fig.
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Table 2. Blood pressure and biochemical profiles during placebo and
gemfibrozil periods
Placebo Gemfibrozil
B:ood pressure mm Hg
Systolic 136 (4) 129 (4)
Diastolic 85 (2) 82 (2)
Serum creatinine mg/dl 1.4 (0.1) 1,5 (0.2)
Serum urea nitrogen mg/d/ 30 (4) 29 (3)
Glomerular filtration rate mI/mm 72 (10) 66 (11)
Serum albumin g/dl 3.0(0.3) 3.2(0.3)
Urine protein mg/mg creatinine 3.5 (0.5) 4.5 (1.1)
0
Placebo Gemfibrozil Placebo Gemfibrozil
Fig. 1. Changes in serum triglyceride concentration (A), total choles-
terol (B), low-density lipoprotemn (C) cholesterol and high-density
lipoprotemn (D) cholesterol during placebo and gemfibrozil periods.
Values for individual patients are denoted by closed circles. Mean
values for all patients are denoted by open circles. Placebo vs.
gemfibrozil period: P = 0.001 for triglycerides, P = 0.003 for total
cholesterol, P = NS for LDL cholesterol and P = 0.006 for HDL
cholesterol.
1, Table 3). High-density lipoprotein cholesterol rose 17.8% (P
= 0.006, Fig. 1). Mean LDL cholesterol fell 12.5% (P = 0.08).
Table 3. Plasma lipids and lipoproteins during placebo and
gemfibrozil periods
N Placebo Gemfibrozil P =
Total cholesterol mg/dl 11 372 20 316 15 0.003
Triglycerides mg/dl 11 308 44 152 20 0.001
HDL cholesterol mg/dl 11 43 4 51 4 0.006
LDL cholesterol mg/d/ 11 272 24 238 16 NS
LDL:HDL cholesterol 11 6.60 0.51 4.94 0.42 0.01
Apolipoprotein A-I mg/dl 10 177 10 167 11 NS
Apolipoprotein B mg/dI 10 171 11 126 II 0.006
I I
Placebo Gemfibrozil
Fig. 2. Mass ratios of LDL cholesterol:HDL cholesterol in placebo
control and gemfibrozil periods. Open circles denote the mean values of
11 individual patients, P = 0.01.
The ratio of LDL to HDL cholesterol fell 25.2% (P = 0.01,
Fig. 2, Table 3). Apolipoprotein B fell 26.3% (P = 0.006).
Apolipoprotein A-I concentration did not change (P> 0.05). An
increase in HDL cholesterol but not apoA-I, has been observed
previously during treatment with gemfibrozil, consistent with a
shift in HDL lipid composition [221. There were no significant
correlations either between the changes in apoA-I and HDL
cholesterol concentration, or between the changes in plasma
triglyceride concentration and apoB. Individual differences in
response to gemfibrozil were notable (Figs. 1 to 3). The most
consistent changes, predictable from the known pharmacolog-
ical properties of the fibric acid congeners [23], were reduced
plasma triglycerides and total cholesterol, and increased HDL
cholesterol concentrations.
Despite gemfibrozil treatment both plasma total cholesterol
(in excess of 316 mg'dl in all 11 patients) and mean LDL
cholesterol (238 mg/dl) remained elevated; both exceeded de-
sirable age- and sex-adjusted cutpoints [1,2,241. Seven patients
elected to take colestipol in addition to gemfibrozil but four
eventually dropped out because of gastrointestinal side effects.
In the three patients who completed the third phase, total
a P < 0.05 placebo vs. gemfibrozil
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Placebo Gemfibrozil Placebo Gemfibrozil
Fig. 3. Serum concenirations of apolipoprotein B (A) and apolipoprotein A-I (B) in mg/dl. Open circles denote the mean values of 10 patients.
Placebo vs. gemfibrozil period: P = 0.006 for apo B and P> 0.05 for apo A-l.
cholesterol decreased further by 26% (347 50 to 257 65
mg/dl) and triglycerides fell 17% from 159 110 to 132 110
mg/dl. The HDL cholesterol did not change (54 20 vs. 54 21
mg/dl). Low-density lipoprotein cholesterol decreased 36% (277
65 to 176 46 mgldl) and the LDL/HDL ratio fell 33% (5.34
1.25 to 3.57 1.61). Apoprotein B decreased 30% (137 42
to 96 28 mgldl). Neither apoprotein A-I nor serum creatinine
changed. Thus, the lipid and lipoprotein abnormalities present
during monotherapy with gemfibrozil were normalized in the
three patients who completed the third period.
Only 1 of the 11 patients had any adverse effects attributable
to gemfibrozil. Patient #2, who had asymptornatic, mildly-
elevated pretreatment serum creatine phosphokinase (CPK, 576
U/liter), had a marked rise in CPK to 7500 U/liter after a
vigorous 4 hour bicycle trip in the mountains while receiving
gemfibrozil. A follow-up value obtained within four days while
remaining on gemfibrozil was within normal limits and the
patient completed therapy uneventfully. At that time he had
mild muscle aches but no evidence of myoglobinuria. Serum
potassium did not change with gemfibrozil therapy in any
patient.
Discussion
The typical abnormalities of nephrotic hyperlipidemia, in-
creased total plasma and LDL cholesterol with reduced HDL
cholesterol concentrations [25], are potent cardiovascular risk
factors in non-nephrotic individuals [241. Many nephrotic pa-
tients also have hypertriglyceridemia, a factor whose role in
premature atherogenesis is still unclear [26]. Autopsy studies of
young adult nephrotics have shown striking acceleration of
coronary atherosclerosis [91. Despite these features there has
been disagreement over whether hyperlipidemic nephrotic pa-
tients are at increased risk and consequently, over whether they
should receive lipid-lowering drug treatment [10]. A critical
analysis of the literature 171 supports the conclusion that
nephrotic patients are at substantially increased risk, provided
one excludes those whose nephrosis and secondary hypercho-
lesterolemia are self-limited and of short duration.
Studies of non-nephrotic adult males have clearly established
that cholesterol-lowering drugs can reduce morbidity from
ischemic heart disease. In the Lipid Research Clinic's Primary
Prevention Trial, cholesterol-lowering with a bile acid-binding
resin, cholestyramine, reduced coronary morbidity and mortal-
ity by an amount calculated to be 2% for every 1% decrease in
total cholesterol [1, 2]. Comparable benefit in venous coronary
artery bypass graft patency was reported with nicotinic acid and
bile-acid binding resin in the Cholesterol-Lowering Atheroscle-
rosis Study (CLAS) trial [3]. In the Helsinki heart study [4], a
randomized, double-blinded, five-year study of more than 4,000
middle-aged hyperlipidemic men, gemfibrozil reduced total and
LDL cholesterol with a 34% reduction in the incidence of
coronary heart disease. If these findings could be extrapolated
to hyperlipidemic nephrotic patients, effective lipid-lowering
drug therapy can be expected to reduce cardiovascular risk in
them as well.
There have been few controlled studies of lipid-lowering
therapy in nephrotic syndrome. Clofibrate, as noted above,
causes significant muscle toxicity, related to its reduced serum
binding in hypoalbuminemic recipients [13, 14]. Monotherapy
with the bile-acid binding resins, cholestyramine or colestipol
decreases total and LDL cholesterol concentrations [27, 28].
Probucol given alone or with colestipol decreases total and
LDL cholesterol but HDL cholesterol also decreases [28, 29].
The efficacy of probucol in atherosclerosis prevention in hu-
mans has not been established; in animals it appears to protect
through its antioxidant properties rather than its ability to
A B
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modify serum lipoprotein concentrations [301. In a study of
three patients with the nephrotic syndrome, 3-hydroxyl-3-
methylgiutaryl coenzyme A reduction inhibitor, lovastatin,
decreased total cholesterol, triglycerides, VLDL-cholesterol,
and LDL-cholesterol and increased HDL-cholesterol [31]. A
recent study compared simvastatin, another HMG CoA reduc-
tase-inhibitor, with cholestyramine in ten patients with the
nephrotic syndrome [32]. Simvastatin produced a 36% reduc-
tion in total cholesterol and a 39% decrease in LDL-cholesterol.
In the present study we showed that the fibric acid congener,
gemfibrozil, reduced total plasma and LDL cholesterol (15 and
13%, respectively). These observations confirm and extend
published information [17]. HDL cholesterol increased signifi-
cantly (18%) whereas apoA-l concentration did not change.
More impressive decreases in total plasma triglyceride and
apoB were observed (51 and 26%), consistent with the known
effects of fibric acid congeners on plasma VLDL. The LDL:
HDL cholesterol ratio decreased, an effect predicting lower risk
of premature atherosclerosis. Gemfibrozil, however, does not
appear to be as effective as the HMG CoA reductase inhibitors
in lowering total and LDL cholesterol.
The nephrotic syndrome is a very heterogeneous disorder. In
addition to their nephrotic syndrome, many of these patients
have multiple factors contributing to their hyperlipidemia such
as antihypertensive agents, steroid therapy and diabetes melli-
tus. Such was the case in our patients. All of our patients were
on antihypertensives, two were diabetic and three were on
steroid therapy. Careful analysis of the data did not identify any
of these factors as being predictive of a response or lack of
response to gemfibrozil.
Gemfibrozil was safe in this study. A single patient whose
pretreatment CPK was minimally increased had a transient rise
in CPK following vigorous exercise. While he remained on
gemfibrozil, CPK was found to be within normal limits. The
patient was allowed to complete the trial and experienced no
further adverse events. In no patient were there changes in
renal function or proteinuria. A small but statistically significant
decrease in diastolic blood pressure, not reported in other
studies of gemfibrozil, was observed; it is likely that this was
due to chance rather than the result of treatment. A recent
study has shown that the plasma half-life of gemfibrozil is
independent of renal function [33]. Thus, the dose of gemfi-
brozil, unlike that of clofibrate, does not need to be adjusted in
the presence of renal failure [33].
Despite improvement in their lipid profiles during gemfibrozil
therapy, patients' total and LDL cholesterol concentrations
remained substantially above desirable limits [24]. Thus the
effect of simultaneous bile acid-binding resin treatment with
colestipol was of interest. Only three of seven patients com-
pleted a six week trial of colestipol and gemfibrozil together;
four patients dropped out because of gastrointestinal side
effects. In the three who completed the trial there was a further
26% decrease in total cholesterol, a 36% decrease in LDL
cholesterol, and a 17% decrease in plasma triglycerides, com-
pared to gemfibrozil alone. Exacerbation of hypertriglyceri-
demia during resin therapy, known to occur in predisposed
hypertriglyceridemic patients [34], was not observed. On the
basis of these limited observations in three patients, combina-
tion therapy appeared to be much more effective in normalizing
nephrotic hyperlipidemia than treatment with gemfibrozil alone.
Further studies of combined gemfibrozil-resin therapy in
nephrotic syndrome are needed, as are comparative studies
with HMG CoA reductase inhibitors that may be better toler-
ated by patients than bile acid-binding resins. The clinician
should, however, be aware that both lovastatin and gemfibrozil
have produced myositis [35, 36]. Although some investigators
have used these two drugs together, this should be done
cautiously since their toxicities may be additive [35].
It has been suggested that hyperlipidemia itself may promote
progression of chronic renal disease [37], a hypothesis sup-
ported by some experimental evidence. In a renal ablation
model of chronic renal failure in the rat, control of hyperlipid-
emia with drug therapy slowed the development of glomerulo-
sclerosis [38]. In aminonucleoside nephrosis in the rat, dietary
cholesterol supplementation exacerbated the development of
glomerulosclerosis [39]. However, we were unable to detect
improvement in either proteinuria or serum creatinine during
lipid-lowering treatment in this short-term study.
Nephrotic hyperlipidemia can be treated safely with gemfi-
brozil for at least six weeks with improvement in atherogenic
serum lipid and lipoprotein abnormalities. Inspite of this obser-
vation and that gemfibrozil treatment reduces coronary risk in
non-nephrotic hyperlipidemic men, monotherapy with gemfi-
brozil is not likely to be satisfactory for the majority patient
with severe nephrotic hypercholesterolemia. The HMGCoA
reductase inhibitors, lovastatin and simvastatin, are potent
agents in reducing total and LDL cholesterol in the majority of
hypercholesterolemic individuals, with or without nephrotic
syndrome. They are well tolerated in the short term, but more
experience is needed to establish their long term safety and
efficacy in reducing coronary risk. Until such information
becomes available, treatment with gemfibrozil alone or in
combination with bile acid-binding resins remains a reasonable
option. Patients so treated should be followed carefully with
measurements of total and LDL cholesterol and alternative
treatment should be undertaken if adequate responses fail to
occur.
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